Skip to content

Study · Randomized controlled trial · n = 25 · 2024

5 results

Oxytocin does not acutely improve glucose tolerance in men with type 2 diabetes.

Goll N, Moszka N, Kantartzis K, Preissl H, Gruber T, Fritsche L, Jumpertz-von Schwarzenberg R, García-Cáceres C, Fritsche A, Hallschmid M

Diabetes, obesity & metabolism8 Aug 2024Cited by 2 (Europe PMC)

PMID39118203 (opens in a new tab)DOI10.1111/dom.15812 (opens in a new tab)PepBankPUB-39118203
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In men with type 2 diabetes, intranasal oxytocin increased plasma oxytocin concentrations compared with placebo.

    In plain wordsIn men with type 2 diabetes, nasal oxytocin raised blood oxytocin levels more than placebo did.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin concentration
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Oxytocin compared with placebo increased plasma oxytocin concentrations
    1 context sentence
    Summary · context
    In a double-blind, crossover comparison, intranasal oxytocin (24 IU) and placebo, respectively, were administered to 25 fasted men with non-insulin-treated type 2 diabetes
  2. 02HumanRandomized controlled trialOther

    In men with type 2 diabetes, intranasal oxytocin reduced heart rate compared with placebo.

    In plain wordsIn men with type 2 diabetes, nasal oxytocin lowered heart rate more than placebo did.

    Peptide
    Oxytocin
    Outcome
    DecreaseHeart rate
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    Oxytocin compared with placebo increased plasma oxytocin concentrations and reduced the heart rate
    1 context sentence
    Summary · context
    In a double-blind, crossover comparison, intranasal oxytocin (24 IU) and placebo, respectively, were administered to 25 fasted men with non-insulin-treated type 2 diabetes
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with type 2 diabetes, intranasal oxytocin did not change the glucose area under the curve after an oral glucose tolerance test compared with placebo.

    In plain wordsIn men with type 2 diabetes, nasal oxytocin did not change blood sugar after a glucose drink compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeGlucose AUC after oGTT
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Measurements

    Glucose AUC
    2240 mmol/L × min
    oxytocin
    Glucose AUC
    2190 mmol/L × min
    placebo

    Source sentences

    Summary
    but did not alter glucose metabolism in the 3 hours after oGTT onset (area under the curve, glucose, 2240 ± 80.5 vs. 2190 ± 69.5 mmol/L × min; insulin, 45 663 ± 4538 vs. 44 343 ± 4269 pmol/L × min; C-peptide, 235 ± 5.1 vs. 231 ± 15.9 nmol/L × min).
    1 context sentence
    Summary · context
    In a double-blind, crossover comparison, intranasal oxytocin (24 IU) and placebo, respectively, were administered to 25 fasted men with non-insulin-treated type 2 diabetes
  4. 04HumanRandomized controlled trialEfficacy outcome

    In men with type 2 diabetes, intranasal oxytocin did not change the insulin area under the curve after an oral glucose tolerance test compared with placebo.

    In plain wordsIn men with type 2 diabetes, nasal oxytocin did not change insulin levels after a glucose drink compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeInsulin AUC after oGTT
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    but did not alter glucose metabolism in the 3 hours after oGTT onset (area under the curve, glucose, 2240 ± 80.5 vs. 2190 ± 69.5 mmol/L × min; insulin, 45 663 ± 4538 vs. 44 343 ± 4269 pmol/L × min; C-peptide, 235 ± 5.1 vs. 231 ± 15.9 nmol/L × min).
    1 context sentence
    Summary · context
    In a double-blind, crossover comparison, intranasal oxytocin (24 IU) and placebo, respectively, were administered to 25 fasted men with non-insulin-treated type 2 diabetes
  5. 05HumanRandomized controlled trialEfficacy outcome

    In men with type 2 diabetes, intranasal oxytocin did not change the C-peptide area under the curve after an oral glucose tolerance test compared with placebo.

    In plain wordsIn men with type 2 diabetes, nasal oxytocin did not change C-peptide levels after a glucose drink compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeC-peptide AUC after oGTT
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Measurements

    C-peptide AUC
    235 nmol/L × min
    oxytocin
    C-peptide AUC
    231 nmol/L × min
    placebo

    Source sentences

    Summary
    but did not alter glucose metabolism in the 3 hours after oGTT onset (area under the curve, glucose, 2240 ± 80.5 vs. 2190 ± 69.5 mmol/L × min; insulin, 45 663 ± 4538 vs. 44 343 ± 4269 pmol/L × min; C-peptide, 235 ± 5.1 vs. 231 ± 15.9 nmol/L × min).
    1 context sentence
    Summary · context
    In a double-blind, crossover comparison, intranasal oxytocin (24 IU) and placebo, respectively, were administered to 25 fasted men with non-insulin-treated type 2 diabetes

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.